OPG/sRANKL ratio

There is 1 paper on OPG/sRANKL ratio in aging research: 1 observational study in people. The newest story, Oct 22, 2026: “Denosumab linked to greater grip strength gains in women”.

Biomarker

1 paper studies it1 finding

1 new paper in 30 daysSee all 1 papers on OPG/sRANKL ratio

“The OPG/sRANKL ratio increased more strongly at 12 months (2.503 [2.053, 3.429] vs. 0.807 [0.549, 0.994], p < 0.001).”
Denosumab Versus Zoledronic Acid for Muscle Strength and Physical Performance in Postmenopausal Osteoporosis: A 3-Year Prospective StudyJournal of cachexia, sarcopenia and muscle2026doi:10.1002/jcsm.70406
  • Humans1

Associations

1

Denosumab

upin humans1

1 study
  1. Denosumab is associated with OPG/sRANKL ratio in humans (Compared with zoledronic acid) (2.503 [2.053, 3.429] vs. 0.807 [0.549, 0.994]).

    “The OPG/sRANKL ratio increased more strongly at 12 months (2.503 [2.053, 3.429] vs. 0.807 [0.549, 0.994], p < 0.001).”

    HumansCompared with zoledronic acid12 monthsfemalesn = 186

    Denosumab linked to greater grip strength gains in women

    Journal of cachexia, sarcopenia and muscle

More on Denosumab

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months
Journal of Cachexia, Sarcopenia and Muscle

Denosumab linked to greater grip strength gains in women

At 12 months, grip strength rose 1.45 kg with denosumab versus 0.66 kg with zoledronic acid in postmenopausal women with osteoporosis.At 12 months, grip strength rose 1.45 kg with denosumab versus 0.66 kg with zoledronic acid in postmenopausal women with osteoporosis.

Cohort · 186 peopleDenosumab